The Effects of Weight Loss on Renal Function in Patients with Severe Obesity

AVRY CHAGNAC, TALI WEINSTEIN, MICHAL HERMAN, JUDITH HIRSH, UZI GAFTER, and YAACOV ORI
Department of Nephrology, Rabin Medical Center-Golda Campus, Petah Tikva; Tel Aviv University Medical School, Tel Aviv, Israel.

Abstract. Severe obesity is associated with increased renal plasma flow (RPF) and glomerular filtration rate (GFR). The aim of the present study was to examine whether weight loss may reverse glomerular dysfunction in obese subjects without overt renal disease. Renal glomerular function was studied in eight subjects with severe obesity (body mass index [BMI] 48.0 ± 2.4) before and after weight loss. Nine healthy subjects served as controls. GFR and RPF were determined by measuring inulin and PAH clearance. In the obese group, GFR (145 ± 14 ml/min) and RPF (803 ± 39 ml/min) exceeded the control value by 61% (90 ± 5 ml/min, P = 0.001) and 32% (610 ± 41 ml/min, P < 0.005), respectively. Consequently, filtration fraction was increased.

Severe obesity is associated with increased systemic arterial pressure (1), high renal plasma flow (2–4), increased GFR (2,5), and enhanced albumin excretion rate (6,7). We have previously studied glomerular hemodynamics in patients with severe obesity by measuring the fractional clearances of dextran of broad size distribution (8). Analysis of the dextran sieving data, using a theoretical model of macromolecule transport through a heteroporous membrane, showed that the glomerular capillary bed was subjected to an elevated transcapillary hydraulastic pressure gradient resulting in hyperfiltration. In addition to these physiologic abnormalities, many reports have associated obesity with the occurrence of nephrotic syndrome and renal failure (9–19). Obesity-related glomerulopathy was recently defined morphologically as glomerulomegaly with or without focal segmental glomerulosclerosis (20). Obesity may also accelerate the course of idiopathic glomerular disease, such as IgA glomerulopathy (21). The prevalence of obesity-related glomerulopathy, which may lead to end-stage renal disease, has increased tenfold over the last 15 yr as a consequence of “the spread of the obesity epidemic” (22). Although a cause-and-effect relationship between the obesity-associated glomerular hyperfunction and the development of nephrotic syndrome and renal failure has not been demonstrated, experimental and clinical data suggest that hyperfiltration and glomerulomegaly may lead to glomerular damage. Therefore, reducing glomerular hyperfiltration may provide a way to prevent or delay the development of renal disease in the obese.

The aim of the present study was to examine whether weight loss might reverse glomerular dysfunction in obese subjects without overt renal disease.

Materials and Methods
Study Population
Seventeen volunteers, ten women and seven men, aged 23 to 46 yr participated in the study. Eight subjects had severe obesity (body mass index [BMI] > 38), and nine were non-obese, healthy subjects, who served as a control group. All participants denied a history of renal disease. None were treated for hypertension, diabetes mellitus, or any other chronic disease. All were found to have a normal serum creatinine level and a negative dipstick test for urinary protein. Table 1 shows the characteristics of the two groups. Age and gender distributions were similar in the two groups. The body weight of the obese group was more than twice the weight of the control group. BMI of the obese subjects varied between 38.1 and 61.3, with all but one

Copyright © 2003 by the American Society of Nephrology
DOI: 10.1097/01.ASN.0000068462.38661.89
Table 1. General characteristics of the study population

<table>
<thead>
<tr>
<th></th>
<th>Obese Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>Gender (f/m)</td>
<td>4/4</td>
<td>NS</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>36 ± 2</td>
<td>31 ± 2</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.73 ± 0.04</td>
<td>1.70 ± 0.03</td>
</tr>
<tr>
<td>BW (kg)</td>
<td>145 ± 9</td>
<td>64.7 ± 3.1</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>48.0 ± 2.4</td>
<td>22.2 ± 0.6</td>
</tr>
</tbody>
</table>

*a* S, significant, per definition; NS, not significant.

**Study Protocol**

Patients underwent an oral glucose tolerance test (OGTT) and renal function tests. The OGTT was performed at 8 a.m. after a 10-h fast. The subjects ingested 75 g of glucose dissolved in water. Blood samples were withdrawn through an indwelling intravenous catheter 10 min and 1 min before and 60 and 120 min after the ingestion for measurement of plasma glucose and insulin. Urine samples, obtained 1 wk before renal function tests were performed, were assayed for urea, creatinine, and sodium concentration. Renal function tests were performed 4 to 5 d later in all subjects. Each subject was studied at 8 a.m. after a light breakfast low in protein content. The subjects were kept recumbent in a hospital bed, and intravenous catheters were placed in each upper limb for infusion of clearance markers and blood sampling. A priming dose of inulin (50 mg/kg), p-aminohippuric acid (PAH) (8 mg/kg), and dextran 40 (130 mg/kg) was administered. Inulin, PAH, and dextran 40 were thereafter infused continuously. A water load (15 ml/kg) was given during the first 60-min prime. Four accurately timed urine collections were then obtained by spontaneous voiding. Peripheral venous blood was drawn to bracket each urine collection. BP was measured during each urine collection.

The obese patients underwent gastroplasty 1 to 3 wk after performance of the renal function tests. Renal function tests and oral glucose tolerance tests were repeated at least 12 mo after surgery using the same protocol.

The nine control subjects and six of the eight obese subjects were part of a larger group recruited for the study of glomerular hemodynamics in obesity (8). Dextran 40, a dextran solution of broad size distribution, was administered for the measurement of sieving coefficients of macromolecules to all participants, obese subjects, before and after weight loss, and control subjects. The analysis of the sieving coefficients of dextran in the control group and in the obese group before surgery was the subject of our initial report (8). Serum and urine dextran concentrations were not measured after weight loss. However, the dextran solution was administered to maintain standard conditions during the studies before and after weight loss.

**Laboratory Procedures**

Plasma and urinary concentrations of inulin and PAH were analyzed by colorimetric methods (23,24). Plasma glucose, serum albumin, serum pre-albumin, serum transferrin, blood total lymphocyte count, and urine urea, creatinine, and sodium were measured using standard laboratory methods. Serum insulin was measured using a RIA (Sorin-Biomedica, Saluggia, Italy). Urine albumin was measured by nephelometric methods (Beckman, Galway, Ireland).

**Calculations**

GFR was determined from the average inulin clearance. RPF was calculated by dividing the average PAH clearance by an assumed renal PAH extraction ratio of 0.9. The urine urea/creatinine ratio (mg/mg) and the urine sodium/creatinine ratio (mEq/mg) were used to estimate the change in protein and sodium intake after weight loss. Mean arterial pressure was calculated as diastolic pressure plus one third of the pulse pressure. BMI was calculated as: BMI = BW/H², where BW is the body weight expressed in kg and H is the height expressed in m. OGTT was analyzed by calculating the area under the glucose and insulin curves. Changes in GFR (ΔGFR), BMI (ΔBMI), area under the glucose and insulin curves (ΔAUCgluc and ΔAUCins), and in systolic BP (ΔSBP) after weight loss were expressed as % change from baseline.

**Statistical Analyses**

Normally distributed data are expressed as mean ± SEM. Variables with skewed distribution, such as urinary albumin excretion rate and fractional albumin clearance, are expressed as median (range). The significance of differences between the obese and control groups was evaluated by a two-tailed t test. The significance of differences between the obese group before and after weight loss was evaluated by a paired two-tailed t test. t test was applied to non-normally distributed data after log transformation. Potential relationships between ΔGFR (dependent parameter) and ΔBMI, ΔAUCgluc, ΔAUCins, and ΔSBP (independent parameters) were analyzed by linear regression (univariate analysis). Multivariate analysis was performed with logistic regression using forward stepwise selection.

Informed consent was obtained from all participants. The study was approved by the local Ethics Committee.

**Results**

Obese patients lost 48 kg within 12 to 17 mo, from 145 ± 9 to 97 ± 7 (P < 0.0005), and BMI decreased by 16 units, from 28.4 ± 2.4 to 32.1 ± 1.5 (P < 0.0001). Despite this decrease, BMI remained well above normal (control group: 22.2 ± 1.7, P < 0.0001).

**Oral Glucose Tolerance Test**

Table 2 summarizes the results of the OGTT. Fasting blood glucose was higher in the obese group compared with the control group, all values being below 140. Fasting insulin was elevated almost threefold in the obese group. The area under the glucose and the insulin curves in the obese group were increased by 80 and 250% respectively, as compared with the control group. The ratio of the insulin-to-glucose area under the curves of the obese group was increased by 85%, suggesting insulin resistance.

After surgery, fasting serum glucose and the area under the glucose and insulin curves decreased significantly. The ratio of the insulin-to-glucose area under the curves decreased by 32%, reaching a value 27% above the normal. These data are consistent with improvement in insulin resistance.

**Nutritional Parameters**

The urine urea/creatinine ratio decreased from 17.1 ± 1.9 to 11.8 ± 1.3 (P < 0.05) after weight loss. The urine sodium/creatinine ratio decreased from 0.16 ± 0.01 to 0.12 ± 0.02 (P < 0.05). Serum albumin was 4.2 ± 0.1 before surgery and 4.3 ± 0.1 mg/dl after weight loss (P = NS). Serum pre-albumin was 27.3 ± 3.1 before surgery and 25.3 ± 1.0 mg/dl after weight loss (P = NS). Serum transferrin was 312 ± 13 before
surgery and 314 ± 21 mg/dl after weight loss (P = NS). Total blood lymphocyte count was 1946 ± 186 before surgery and 1728 ± 146/mm³ after weight loss (P = NS).

**Filtration Dynamics**

Filtration dynamics and arterial pressure data are shown in Table 3. In the obese group, systolic arterial pressure was in the high-normal range. Diastolic and mean arterial pressures were normal. However, these values were higher than those of the control group.

GFR was 61% higher in the obese than in the control group. It was elevated in six of the eight patients. The increase in RPF was proportionally smaller, averaging 32%. The increase in GFR was thus associated with an increase in filtration fraction. After weight loss, GFR and RPF decreased by 24% and 13%, respectively (Figures 1 and 2). Systolic pressure decreased by 10 mmHg, diastolic pressure remained unchanged, and mean arterial pressure decreased nonsignificantly.

**Albumin Excretion**

After weight loss, albumin excretion rate decreased from 16 µg/min (4 to 152 µg/min) to 5 µg/min (3 to 37 µg/min) (P < 0.01), and the fractional clearance of albumin decreased from 3.2×10⁻⁶ (1.1 to 23×10⁻⁸) to 1.2×10⁻⁶ (0.5 to 6.8×10⁻⁶) (P < 0.02).

---

**Table 2. Oral glucose tolerance test in control and obese subjects**

<table>
<thead>
<tr>
<th></th>
<th>Obese Pre-Surgery</th>
<th>P (Post versus Pre)</th>
<th>Obese Post-Surgery</th>
<th>P (Post versus Control)</th>
<th>Control</th>
<th>P (Pre versus Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>8</td>
<td></td>
<td>8</td>
<td></td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Plasma glucose baseline (mg/dl)</td>
<td>113 ± 5</td>
<td>0.01</td>
<td>94 ± 1</td>
<td>NS</td>
<td>92 ± 4</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td></td>
<td>60 min (mg/dl)</td>
<td>207 ± 16</td>
<td>0.01</td>
<td>143 ± 13</td>
<td>0.02</td>
<td>102 ± 9</td>
</tr>
<tr>
<td></td>
<td>120 min (mg/dl)</td>
<td>160 ± 16</td>
<td>&lt;0.02</td>
<td>102 ± 10</td>
<td>NS</td>
<td>87 ± 4</td>
</tr>
<tr>
<td>Plasma insulin baseline (U/ml)</td>
<td>40 ± 10</td>
<td>&lt;0.02</td>
<td>15 ± 2</td>
<td>NS</td>
<td>14 ± 1</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td></td>
<td>60 min (U/ml)</td>
<td>173 ± 16</td>
<td>&lt;0.005</td>
<td>100 ± 21</td>
<td>&lt;0.05</td>
<td>50 ± 5</td>
</tr>
<tr>
<td></td>
<td>120 min (U/ml)</td>
<td>135 ± 23</td>
<td>&lt;0.005</td>
<td>37 ± 7</td>
<td>NS</td>
<td>34 ± 4</td>
</tr>
<tr>
<td>AUC (arbitrary units)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC_GLU</td>
<td>343 ± 24</td>
<td>&lt;0.01</td>
<td>241 ± 16</td>
<td>&lt;0.02</td>
<td>189 ± 10</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>AUC_INS</td>
<td>261 ± 29</td>
<td>&lt;0.0005</td>
<td>127 ± 2</td>
<td>0.001</td>
<td>74 ± 6</td>
<td>&lt;0.00001</td>
</tr>
<tr>
<td>AUC_INS/AUC_GLU</td>
<td>0.76 ± 0.06</td>
<td>&lt;0.005</td>
<td>0.52 ± 0.08</td>
<td>&lt;0.05</td>
<td>0.41 ± 0.04</td>
<td>&lt;0.0005</td>
</tr>
</tbody>
</table>

* AUC, area under the curve; AUC_INS, area under the insulin curve; AUC_GLU, area under the glucose curve.

**Table 3. Filtration dynamics and arterial pressure in control and obese subjects**

<table>
<thead>
<tr>
<th></th>
<th>Obese Pre-Surgery</th>
<th>p (Post versus Pre)</th>
<th>Obese Post-Surgery</th>
<th>p (Post versus Control)</th>
<th>Control</th>
<th>p (Pre versus Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>8</td>
<td></td>
<td>8</td>
<td></td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>GFR (ml/min)</td>
<td>145 ± 14</td>
<td>0.01</td>
<td>110 ± 7</td>
<td>&lt;0.05</td>
<td>90 ± 5</td>
<td>0.001</td>
</tr>
<tr>
<td>RPF (ml/min)</td>
<td>803 ± 39</td>
<td>&lt;0.02</td>
<td>698 ± 42</td>
<td>NS</td>
<td>610 ± 41</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>FF</td>
<td>0.178 ± 0.010</td>
<td>0.07</td>
<td>0.158 ± 0.007</td>
<td>NS</td>
<td>0.149 ± 0.008</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>SYS (mmHg)</td>
<td>143 ± 6</td>
<td>&lt;0.005</td>
<td>133 ± 6</td>
<td>&lt;0.05</td>
<td>120 ± 2</td>
<td>0.001</td>
</tr>
<tr>
<td>DIAS (mmHg)</td>
<td>80 ± 3</td>
<td>NS</td>
<td>78 ± 4</td>
<td>NS</td>
<td>70 ± 3</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>101 ± 4</td>
<td>&lt;0.1</td>
<td>97 ± 5</td>
<td>NS</td>
<td>86 ± 2</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

* GFR, glomerular filtration rate; RPF, renal plasma flow; FF, filtration fraction; SYS, systolic arterial pressure; DIAS, diastolic arterial pressure; MAP, mean arterial pressure.

---

Figure 1. GFR in the obese group before and after weight loss.
been previously shown (2). Albuminuria, improve substantially after weight loss. It has

jects. In the only study previously published on the effects of microalbuminuria all decrease after weight loss in obese sub-

decrease in GFR, as shown by the decrease in the fractional albumin clearance.

solely due to a decrease in GFR, as shown by the decrease in mean arterial pressure than the control group. We have previ-

counts for the increased GFR, the increased glomerular pres-

Discussion

This study shows that the renal hemodynamic abnormalities associated with severe obesity, i.e., augmented GFR, RPF, and albuminuria, improve substantially after weight loss. It has been previously shown (2–4,8) that obesity-associated hyperfiltration is associated with a high RPF, suggesting a state of renal vasodilatation involving, mainly or solely, the afferent arteriole. The obese group had a higher systolic pressure and mean arterial pressure than the control group. We have previ-

using a heteroporous model of glomerular size selectivity (8), in a group of 12 extremely obese subjects, which included six of the eight patients studied in the present study. This analysis showed that an increased transcapillary pressure gradient ac-

tivated with intestinal bypass surgery often leads to marked malnutrition. In the present study, the patients underwent gas-

Figure 2. RPF in the obese group before and after weight loss.

Picketers of the Changes in GFR

By univariate analysis, ΔGFR correlated with ΔAUC\text{gluc} (r = 0.76, P < 0.03). The correlation between ΔGFR and ΔBMI approached significance (r = 0.69, P = 0.059). ΔAUC\text{ins} (r = 0.33, P = NS) and ΔSBP (r = 0.37, P = NS) were not predictors of ΔGFR. By multivariate analysis, joining ΔSBP to ΔAUC\text{gluc} resulted in an increased correlation with ΔGFR: r = 0.95, P = 0.01.

We wish to emphasize that the GFR in the present study has not been corrected for body surface area. The number of nephrons does not increase with increasing body fat; therefore, increasing obesity must result in an increase in the single nephron GFR. Absolute GFR reflects this phenomenon, whereas correcting GFR for body surface area obscures it. We have accordingly analyzed the data by using the uncorrected, absolute GFR.

What are the long-term consequences of the improvement in the hemodynamic properties of the glomeruli? Obesity-related glomerular disease was first reported almost three decades ago by Weisinger et al. (9). Since then, numerous reports have been published (10–20). This glomerulopathy often presents as nephrotic syndrome, with or without renal failure. The prevalence of glomerular disease in the obese is unknown. A recent publication reported that the prevalence of obesity-related glomerulopathy, morphologically defined as glomerulomegaly with or without focal segmental glomerulosclerosis, has increased tenfold over 15 yr (20). Its pathogenesis is unascertained. However, considering that the glomeruli of patients with severe obesity are subjected to an elevated transcapillary filtration pressure gradient and to an elevated filtration rate (8), it is tempting to speculate that these physiologic abnormalities underlie glomerular damage. Brenner et al. (25,26) suggested two decades ago that adaptive glomerular changes occur after reduction in functional renal mass and that these changes underlie the initiation and progression of glomerular sclerosis. Glomerular hyperperfusion, hyperfiltration, and hypertension lead to stretching of the glomerular capillary wall, injury to endothelial and epithelial cells, and transudation of macromol-

eules into the mesangium (27). This results in mesangial overload and dysfunction (28,29) and evolves with time to mesangial expansion and sclerosis (30). This mechanism, supported by experimental data, has been proposed to contribute to the progression of diabetic nephropathy in the hyperfiltrating diabetic kidney (31,32). Glomerular hyperfiltration and hyperten-

tion are associated with glomerular hypertrophy in the remnant kidney model and in the diabetic kidney model. It has been suggested that glomerular hypertrophy also concur to the occurrence of glomerulosclerosis (33), by raising glomerular wall tension (34) and by stretching and damaging the glomer-

ular epithelial cells (35).

As shown in the present study and in previous studies by other groups (2,5) and by ours (8), the kidney of the obese patient shares functional abnormalities with the diabetic kidney such as renal vasodilatation and hyperfiltration, rendering it susceptible to damage. It is noteworthy that the decrease in the area under the glucose curve after weight loss was a predictor of the changes in GFR. However, this finding does not necessarily imply a cause and effect relationship between impaired
glucose tolerance and hyperfiltration, and it may reflect the fact that both improve independently following weight loss.

In the present study the elevated RPF and GFR decreased after weight loss. Given the fact that the number of glomeruli remained unchanged during the study, this change reflects a decrease in single-nephron plasma flow, and single-nephron GFR. The decrease in RPF suggests that the glomerular afferent arteriole became less dilated, thus transmitting a lower pressure to the glomerular capillary bed. The resulting decrease in capillary hydrostatic pressure is even more prominent because systemic arterial pressure also decreased. Thus, capillary hydrostatic pressure decreased by two mechanisms: a decrease in systemic arterial pressure and an increased afferent arteriole resistance. This decrease in capillary hydrostatic pressure is expected to diminish GFR. In addition, a decrease in RPF may affect GFR independently of changes in hydrostatic pressure: this decrease is predicted to raise the intraluminal concentration of macromolecules as blood flows axially along the glomerular capillaries (36). This results in an increase in the glomerular intracapillary oncotic pressure, thus lessening the forces favoring glomerular ultrafiltration. It is noteworthy that GFR decreased in all subjects in the present study: in contrast, RPF did not decrease in two of the subjects. The reason for the discrepancy between the change in GFR in all subjects and the lack of decrease in RPF in these two subjects is unknown. In one of these two, RPF was in the normal range before weight loss, a fact that may explain the lack of change after weight loss. However, this finding is consistent with the fact that GFR may change irrespective of variations in RPF.

Finally, the fractional excretion of albumin decreased following weight loss. The mechanisms linking glomerular hemodynamic alterations and the fractional clearance of albumin are uncertain. An increased fractional albumin clearance may be theoretically due to either impaired size- or charge-permeability properties of the glomerular membrane or to decreased tubular catabolism of albumin. The study of glomerular sieving coefficients of dextran molecules of graded size showed that microalbuminuria is not due to a size-selectivity defect (37). Thus, the increased albumin excretion rate may be due to either a glomerular charge-selectivity defect or to decreased tubular catabolism. Recent studies suggest that an increased glomerular pressure may increase albumin excretion rate by affecting glomerular cell metabolism: stretching of mesangial cells by increased pressure (38–40) increases the production of TGF-β, which may impair the lysosomal enzyme activity in tubular cells (41,42). This leads to increased urinary albumin excretion independently of an altered glomerular permeability, as shown in a model of hypertension-induced albuminuria (42). Furthermore, an increased albumin excretion rate in the nondiabetic patient may be the result of systemic endothelial dysfunction, independently of local glomerular hemodynamic alterations. Obesity is associated with endothelial cell dysfunction (43–47), which is one of the factors accounting for the increased cardiovascular morbidity in the obese population (48,49). It is thus possible that the decreased albuminuria after weight loss reflects a beneficial influence of weight loss on the integrity of the systemic capillary network.

Notwithstanding the pathogenesis of albuminuria in the obese subject, the decreased fractional albumin excretion after weight loss reflects improved glomerular and/or systemic capillary function.

The improvement in glomerular hemodynamics after weight loss, shown in the present study was associated with a decrease in BP that correlated by multivariate analysis with the change in GFR. Reisin et al. (50) have shown that weight loss in overweight hypertensive subjects results in a decrease in BP and that this decrease is independent of a reduction in salt-intake. Hall et al. (51) showed in an experimental model that obesity is associated with marked sodium retention. Hall (52) hypothesized that the increased tubular reabsorption of sodium results in decreased delivery of salt to the macula densa, which leads to glomerular arteriolar vasodilatation and to increased RPF and GFR. This hypothesis provides a link between obesity-associated hypertension and hyperfiltration. The decrease in GFR and arterial pressure after weight loss is compatible with this hypothesis. However, this hypothesis remains to be proven.

This study was performed in obese individuals without overt renal disease. Hyperfiltration may be implicated not only in the pathogenesis of obesity-related glomerulopathy, but also in the progression of other glomerulopathies. A recent study demonstrated that IgA nephropathy progresses more rapidly in obese subjects than in lean patients (21). This finding and the results of the present study suggest that weight loss may favorably alter the course of chronic renal insufficiency by reducing the obesity-associated glomerular hyperfiltration. Thus, considering the increasing prevalence of obesity (22) and obesity-associated renal disease (20,21) the findings of the present study have important theoretical and practical implications.

In summary, weight loss improves the glomerular hemodynamic abnormalities associated with severe obesity in subjects without overt renal disease. These findings suggest that weight loss may delay the progression of renal insufficiency in obese patients with glomerular disease.

Acknowledgment

We thank Chaim Chaimoff, MD, Department of Surgery A, Rabin Medical Center-Golda Campus, for his help in recruiting the patients.

References

7. Valensi P, Assayag M, Busby M, Paries J, Lormeau B, Attali JR: Microalbuminuria in obese patients with or without hyperten-
Physiol Renal Physiol 278: F817–F822, 2000
9. Weisinger JR, Kempson RL, Eldridge FL, Swensen RS: The
10. Kasiske BL, Crosson JT: Renal disease in patients with massive
11. Warnke RA, Kempson RL: The nephrotic syndrome in massive
obesity: A study by light, immunofluorescence and electron
12. Wesson DE, Kurtzman NA, Frommer JP: Massive obesity and
segmental glomerulosclerosis associated with obesity and sleep
D: Weight reduction in massive obesity associated with focal
segmental glomerulosclerosis: Another evidence for hyperfiltra-
15. Bailey RR, Lynn KL, Burry AF, Drennan C: Proteinuria, glo-
erulomegaly and focal glomerulosclerosis in a grossly obese
man with obstructive sleep apnea syndrome. Aust NZ J Med 19:
473–474, 1989
Inukai T, Kobayashi I, Kobayashi S: Improvement of nephrotic
syndrome in a massively obese patient after weight loss and
17. Praga M, Hernandez E, Adres A, Leon M, Ruijlope LM, Rodicio
 JL: Effects of body-weight loss and captopril treatment on pro-
teinuria associated with obesity. Nephron 70: 35–41, 1995
18. Praga M, Morales E, Herrero JC, Perez-Campos A, Dominguez-
Gil B, Alegre R, Vara J, Martinez MA: Absence of hypoalbu-
minemia despite massive proteinuria in focal segmental glo-
erulosclerosis secondary to hyperfiltration. Am J Kidney Dis 33:
52–58, 1999
and focal segmental glomerulosclerosis in severely obese adoles-
20. Kambham N, Markowitz S, Valeri AM, Lin J, D’Agati VD:
Obesity-related glomerulonephropathy: an emerging epidemic.
Berthezene F, Bertoux F: Excessive body weight as a new
independent risk factor for clinical and pathological progression
22. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS,
Koplan JP: The spread of the obesity epidemic in the United
24. Brun C: A rapid method for determination of paraaminohippuric
acid in kidney function tests. J Lab Clin Med 37: 955–958, 1951
25. Brenner BM: Hemodynamically mediated glomerular injury and
the progressive nature of kidney disease. Kidney Int 23: 647,
1983
and the progressive nature of kidney disease. New Eng J Med
307: 652–660, 1982
27. Olson JL, de Urdaneta AG, Hepinstall RH: Glomerulohyalinosis
28. Grond J, Elema JD: Glomerular mesangium. Analysis of the
increased activity observed in experimental acute aminonucleo-
side nephrosis in the rat. Lab Invest 45: 400–409, 1981
29. Grond J, Schilthuis M, Koudstaal J, Elema JD: Mesangial func-
tion and glomerular sclerosis in rats after unilateral nephrectomy.
30. Rennke HG: Structural alterations associated with glomerular
31. Hostetter TH, Troy JL, Brenner BM: Glomerular haemodynamics
32. Rudberg S, Persson B, Dahlquist G: Increased glomerular filtra-
tion rate as a predictor of diabetic nephropathy –results from an
33. Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamic
changes vs. hypertrophy in experimental glomerular sclerosis.
34. Daniel BS, Hostetter TH: Adverse effects of growth in the glo-
35. Fries JW, Sandstrom DJ, Meyer TW, Rennke HG: Glomerular
hypertrophy and epithelial cell modulation progressive glo-
erulosclerosis in the rat. Lab Invest 60: 205–218, 1989
36. Deen WM, Robertson CR, and Brenner BM: A model of glo-
erulosclerosis in the rat. Am J Physiol 223: 1178–1183,
1972
37. Lemley KV, Blouch K, Abdulhussain A, Boothroyd DB, Bennett PH,
Myers BD, Nelson RG: Glomerular permselectivity at the onset
11: 2095–2105, 2000
38. Hirakata M, Kaname S, Chung UG, Joki N, Hori Y, Noda M,
Takuya Y, Okazaki T, Fujita T, Katoh T, Kurokawa K: Tyrosine
kinase dependent expression of TGF-beta induced by stretch
Patterson D, Narins RG: Cyclic stretching forces selectively
upregulates TGF-beta isoforms in cultured rat mesangial cells.
40. Li Q, Muragaki Y, Ooshima A: Stretch-induced collagen
synthesis in cultured smooth muscle cells from rabbit aortic media and a possible involvement of angiotensin II
41. Scheng O, Ling H, Sebekova K, Vamvakas S, Brechtel J,
Heidland A: High glucose media enhance the responsiveness of tubular cells to
growth promoters: Effect on lysosomal cathepsins and protein
42. Russo LM, Osicka TM, Bonnet F, Jerums G, Comper WD:
Albuminuria in hypertension is linked to altered lysosomal ac-
tivity and TGF-beta expression. Hypertension 39: 281–286,
2002
43. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel J,
Baron AD: Obesity/insulin resistance is associated with endothe-
lial dysfunction: Implications for the syndrome of insulin resis-
44. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F,
Bosello O, Lechi A: Body fat distribution predicts the degree of
endothelial cell dysfunction in uncomplicated obesity. Int J Obes
23: 936–942, 1999


Access to UpToDate on-line is available for additional clinical information at http://www.jASN.org/